Tuberculosis: Trends, Challenges, and Opportunities in a Resurging MarketDecision ResourcesJune 28, 2006 18 Pages - SKU: DECR1305292 |
|
Point of Care Diagnostics Bundle (POC Diagnostic Markets, POC Diagnostics for Emerging Infectious Diseases, POC Dx in Physician Office Labs)
3/2/2012 | published by: Kalorama Information
Point of Care Diagnostics represents one of the highest-growth industries in testing. This bundle allows Kalorama Information customers to save by purchasing one PDF which contains our most popular previously published reports on point-of-care
|
more...
|
$3,995.00
|
|
2012 Global Tuberculosis Diagnostics Market Outlook: Test Volumes, Sales Forecasts, and Supplier Shares by Country
4/20/2012 | published by: Venture Planning Group
The report presents a detailed analysis of the Tuberculosis diagnostics market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Tuberculosis definition, epidemiology and etiology are reviewed.
|
more...
|
$3,850.00
|
|
Triple Analysis: Lung Cancer, Angiogenesis and Protein Kinase Inhibitors
5/1/2012 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies in Lung Cancer and by the two mechanism/target/effect areas of Angiogenesis and Protein Kinase Inhibitors. Each of these three individual parts is evaluated according to standardized
|
more...
|
$5,175.00
|
|
Triple Analysis: Lung Cancer, Protein Kinase Inhibitors and Antibodies
5/1/2012 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Lung Cancer), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific area (Antibodies). Each of these three individual parts is
|
more...
|
$5,175.00
|
|
Triple Analysis: Lung Cancer, Protein Kinase Inhibitors and Peptides
5/1/2012 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Lung Cancer), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific area (Peptides). Each of these three individual parts is
|
more...
|
$5,175.00
|
|
Bronchopulmonary Dysplasia Global Clinical Trials Review, H1, 2012
4/25/2012 | published by: GlobalData
Bronchopulmonary Dysplasia Global Clinical Trials Review, H1, 2012 Summary GlobalData's clinical trial report, “Bronchopulmonary Dysplasia Global Clinical Trials Review, H1, 2012 provides data on the Bronchopulmonary Dysplasia clinical trial scenario. This report provides elemental information and data
|
more...
|
$1,000.00
|
|
Lung Injury Global Clinical Trials Review, H1, 2012
4/25/2012 | published by: GlobalData
Lung Injury Global Clinical Trials Review, H1, 2012 Summary GlobalData's clinical trial report, “Lung Injury Global Clinical Trials Review, H1, 2012 provides data on the Lung Injury clinical trial scenario. This report provides elemental information and data
|
more...
|
$1,000.00
|
|
Viral Respiratory Tract Infection Global Clinical Trials Review, H1, 2012
4/25/2012 | published by: GlobalData
Viral Respiratory Tract Infection Global Clinical Trials Review, H1, 2012 Summary GlobalData's clinical trial report, “Viral Respiratory Tract Infection Global Clinical Trials Review, H1, 2012 provides data on the Viral Respiratory Tract Infection clinical trial scenario. This
|
more...
|
$1,000.00
|
|
2012 Global Infectious Disease Testing Market Outlook: Growth Opportunities and Strategies
4/20/2012 | published by: Venture Planning Group
The infectious disease testing market is one of the most rapidly growing segments of the in vitro diagnostics industry, and the greatest challenge facing suppliers in the 21st century. Among the main driving forces
|
more...
|
$28,700.00
|
|
Triple Analysis: Breast Cancer, Lung Cancer and Protein Kinase Inhibitors
5/1/2012 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Lung Cancer and by the mechanism/target/effect of Protein Kinase Inhibitors. Each of these three individual parts is evaluated according to standardized
|
more...
|
$5,175.00
|
